Hospital Injectable Products · LP-194
Lidocaine Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-194Hospital Injectable Products
- Generic identity
- LidocaineInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-194
- Generic ingredient
- Lidocaine
- Dosage form
- Injection
- Proposed strength
- 1%; 2%
- Proposed pack
- Ampoule 2 mL / 5 mL / 10 mL
- Portfolio category
- Hospital Injectable Products
About Lidocaine
Lidocaine is a local anaesthetic that blocks transmission of nerve impulses. Certain injectable lidocaine products also have a separate antiarrhythmic role, but those uses and formulations must not be conflated. The catalogue lists injection concentrations without establishing every authorized route or procedure. Local anaesthetic selection requires assessment of the patient, procedure and total exposure from all relevant products.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional use can involve selected forms of local or regional anaesthesia where the exact product is suitable. A formulation used near nerves or in a specialized anatomical space must meet route-specific requirements. The absence or presence of a vasoconstrictor and preservatives matters. This page does not provide a nerve-block technique, infiltration method, injection rate or maximum-exposure calculation, and it does not confirm any specialized route for the candidate.
Important safety considerations
Local anaesthetic systemic toxicity can affect the nervous system and cardiovascular system, causing seizures, arrhythmia or collapse. Intravascular administration errors and excessive cumulative exposure are important hazards. Methemoglobinaemia, allergy and procedure-related injury are further concerns in relevant patients. Review liver function, cardiac disease, other local anaesthetics and interacting medicines. Administration requires trained personnel, observation and access to an appropriate emergency response.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source lists 1% and 2% ampoules in several volumes. Confirm lidocaine salt, strength basis, preservative content and whether any additional active ingredient is present. No neuraxial, intrathecal or antiarrhythmic suitability is inferred.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm procedure, formulation, total local-anaesthetic exposure, patient risks and monitoring. Verify the exact authorized route and emergency preparedness before use.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Lidocaine
- Dosage form / presentation
- Injection
- Catalogue strength
- 1%; 2%
- Catalogue pack
- Ampoule 2 mL / 5 mL / 10 mL
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue lists lidocaine injection at 1% and 2% with 2 mL, 5 mL and 10 mL ampoule sizes. It does not establish the exact lidocaine salt, preservative status, whether every concentration is paired with every ampoule size, or the authorised route/procedure.
- Do not infer epinephrine/vasoconstrictor content, neuraxial suitability, antiarrhythmic use or a full SKU matrix from ingredient and concentration alone.
- Approved indication, patient eligibility and dosing or test interpretation are not established by this portfolio record.
- Registration/authorization, manufacturing or site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- DailyMed: lidocaine hydrochloride injection 1% and 2% — external comparatorgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical/formulation identity, concentration, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-194, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-194.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.